Replies to post #345817 on Amarin Corp Plc (AMRN)

[Pharmacydude]

Ram:
“This current market cannot be worth it to Generics”
Here is the generic’s perspective: due to the assumption that the generic is always cheaper, automatic substitution policies of insurance plans and state laws that require the use of generics when available the generics know they will be able to sell as much as they can produce. Currently they are selling around 15,000/week which is 4.5 Million dollars. It is definitely worth their efforts. They also know the market is very immature and that Amarin has NO choice but to continue to market/advertise/promote the hell out of V because Amarin only gets the generic’s leftovers. If Amarin can grow the market then Amarin will be able to keep part of the US market. Amarin will keep doing all the work and they (generics) will have an ever increasing market for many years.
I think the insurance coverage issues are changing but it will be a while before generics reach the point where not enough payers are willing to buy the generic and their sales decrease.
Generics know that patent laws are completely unenforceable because everybody just blames the other guy and nobody is held responsible.
I do believe that Amarin controls the API and therefore has years before the generics take the majority of the market.
Generics have nothing to lose, 100’s of millions to gain and are very happy with how things are going.
In the end Amarin will do just fine, maintaining US revenue to support EU launch and will be able to grow the US market as more pts and doctors demand that V be covered.